南京新百(600682.SH):子公司擬使用2600萬美元投資東方紅全球配置基金獨立投資組合
格隆匯3月26日丨南京新百(600682.SH)公佈,公司全資子公司ShidingShengwuBiotechnology(HongKong)TradingLimited(世鼎生物技術(香港)有限公司)擬使用2,600萬美元的閒置自有資金投資東方紅全球配置基金獨立投資組合。
獨立投資組合的主要投資目標是通過投資於低風險至中風險產品(如固定收益證券、金融債務和債務相關證券、存款、存單、固定和浮動利率投資證券以及現金或任何其他貨幣市場工具(無論上市與否))尋求長期資本增值,從而獲得投資回報。獨立投資組合還可能審慎把握機會,投資於某些高增長、高風險資產,如風險投資、私募信貸、高收益固定收益證券和私募股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.